Docetaxel and Gemcitabine administered on days 1 and 8 for metastatic non-small cell lung carcinoma (NSCLC): a phase II multicenter trial
Author:
Publisher
Elsevier BV
Subject
Cancer Research,Pulmonary and Respiratory Medicine,Oncology
Reference27 articles.
1. New aspects in staging of lung cancer;Bulzebruck;Cancer,1992
2. Polychemotherapy in advanced non small cell lung cancer: a meta-analysis;Soquet;Lancet,1993
3. Non-Small Cell Lung Cancer Collaborative Group. Chemotherapy in non small cell lung cancer: a meta-analysis using updated data on individual patients from 52 randomized clinical trials. Br Med J 1995;311:899–909.
4. Chemotherapy can prolong survival in patients with advanced non small cell lung cancer: report of a Canadian multicentre randomized trial;Rapp;J. Clin. Oncol,1988
5. Counting the costs of chemotherapy in a National Cancer Institute of Canada randomized trial in non small cell lung cancer;Jaakkimainen;J. Clin. Oncol,1990
Cited by 9 articles. 订阅此论文施引文献 订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献
1. Pulmonary toxicity among cancer patients treated with a combination of docetaxel and gemcitabine: a meta-analysis of clinical trials;Cancer Chemotherapy and Pharmacology;2011-05-06
2. A phase II randomized trial of gemcitabine-docetaxel versus gemcitabine-cisplatin in patients with advanced non-small cell lung carcinoma;Cancer Chemotherapy and Pharmacology;2009-01-13
3. Promising Survival in Patients with Recurrent Non-small Cell Lung Cancer Treated with Docetaxel and Gemcitabine in Combination as Second-Line Therapy;Journal of Thoracic Oncology;2008-09
4. A phase II study of days 1 and 8 combination of docetaxel plus gemcitabine for the second-line treatment of patients with advanced non-small-cell lung cancer and good performance status;Lung Cancer;2007-05
5. Dose-finding study of fixed dose gemcitabine and escalating doses of ifosfamide given on days 1 and 8 in patients with advanced non-small cell lung cancer;Lung Cancer;2006-08
1.学者识别学者识别
2.学术分析学术分析
3.人才评估人才评估
"同舟云学术"是以全球学者为主线，采集、加工和组织学术论文而形成的新型学术文献查询和分析系统，可以对全球学者进行文献检索和人才价值评估。用户可以通过关注某些学科领域的顶尖人物而持续追踪该领域的学科进展和研究前沿。经过近期的数据扩容，当前同舟云学术共收录了国内外主流学术期刊6万余种，收集的期刊论文及会议论文总量共计约1.5亿篇，并以每天添加12000余篇中外论文的速度递增。我们也可以为用户提供个性化、定制化的学者数据。欢迎来电咨询！咨询电话：010-8811{复制后删除}0370
www.globalauthorid.com
TOP
Copyright © 2019-2024 北京同舟云网络信息技术有限公司 京公网安备11010802033243号 京ICP备18003416号-3